Clivel Charlton to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
This is a "connection" page, showing publications Clivel Charlton has written about 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Connection Strength
0.768
-
Muthian G, Mackey V, King J, Charlton CG. Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Neuroscience. 2010 Sep 01; 169(3):1085-93.
Score: 0.371
-
Smith ML, King J, Dent L, Mackey V, Muthian G, Griffin B, Charlton CG. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease. Life Sci. 2014 Aug 06; 110(1):1-7.
Score: 0.122
-
Charlton CG. 1-Methyl-4-phenylpyridinium (MPP+) but not 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) serves as methyl donor for dopamine: a possible mechanism of action. J Geriatr Psychiatry Neurol. 1992 Apr-Jun; 5(2):114-8.
Score: 0.105
-
King JM, Muthian G, Mackey V, Smith M, Charlton C. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease. Life Sci. 2011 Oct 24; 89(17-18):638-43.
Score: 0.101
-
Shepherd KR, Lee ES, Schmued L, Jiao Y, Ali SF, Oriaku ET, Lamango NS, Soliman KF, Charlton CG. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice. Pharmacol Biochem Behav. 2006 Mar; 83(3):349-59.
Score: 0.069